Leptin but not adiponectin is related to type 2 diabetes mellitus in obese adolescents

Pediatric Diabetes

Volumn 17, Issue 4, 2016, Pages 281-288

  Reinehr, Thomas ^a   Woelfle, Joachim ^b   Wiegand, Susanna ^c   Karges, Beate ^d   Meissner, Thomas ^e   Nagl, Katrin ^f   Holl, Reinhard W ^g  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^f UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^g UNIVERSITY OF ULM   (Germany)

Author keywords

Adiponectin; Adolescents; Leptin; Obesity; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; METFORMIN;

ADOLESCENT; ARTICLE; BODY MASS; CAUCASIAN; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; HYPOADIPONECTINEMIA; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; BLOOD; CASE CONTROL STUDY; COMPLICATION;

ADIPONECTIN; ADOLESCENT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LEPTIN; MALE; OBESITY;

EID: 84928024785     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12276     Document Type: Article

References (52)

1. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005: 365: 1333-1346.
2. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003: 46: 3-19.
3. Bluher M. Adipokines - removing road blocks to obesity and diabetes therapy. Mol Metab 2014: 3: 230-240.
4. Roth CL, Reinehr T. Roles of gastrointestinal and adipose tissue peptides in childhood obesity and changes after weight loss due to lifestyle intervention. Arch Pediatr Adolesc Med 2010: 164: 131-138.
5. Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008: 93 (11 Suppl. 1): S64-S73.
6. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008: 93 (11 Suppl. 1): S57-S63.
7. Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin - the classical, resistin - the controversical, adiponectin - the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005: 19: 525-546.
8. Morton GJ. Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol 2007: 583 (Pt 2): 437-443.
9. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000: 62: 413-437.
10. Coppari R, Bjorbaek C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov 2012: 11: 692-708.
11. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008: 52: 1201-1210.
12. Ley SH, Harris SB, Connelly PW et al. Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. Diabetes Care 2008: 31: 1410-1415.
13. Schmidt MI, Duncan BB, Vigo A et al. Leptin and incident type 2 diabetes: risk or protection? Diabetologia 2006: 49: 2086-2096.
14. Abdelgadir M, Elbagir M, Eltom M, Berne C, Ahren B. Reduced leptin concentrations in subjects with type 2 diabetes mellitus in Sudan. Metabolism 2002: 51: 304-306.
15. Morales A, Wasserfall C, Brusko T et al. Adiponectin and leptin concentrations may aid in discriminating disease forms in children and adolescents with type 1 and type 2 diabetes. Diabetes Care 2004: 27: 2010-2014.
16. Rajkovic N, Zamaklar M, Lalic K et al. Relationship between obesity, adipocytokines and inflammatory markers in type 2 diabetes: relevance for cardiovascular risk prevention. Int J Environ Res Public Health 2014: 11: 4049-4065.
17. Al-Hamodi Z, Al-Habori M, Al-Meeri A, Saif-Ali R. Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and type 2 diabetes mellitus. Diabetol Metab Syndr 2014: 6: 99.
18. Stringer DM, Sellers EA, Burr LL, Taylor CG. Altered plasma adipokines and markers of oxidative stress suggest increased risk of cardiovascular disease in First Nation youth with obesity or type 2 diabetes mellitus. Pediatr Diabetes 2009: 10: 269-277.
19. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005: 288: H2031-H2041.
20. Statnick MA, Beavers LS, Conner LJ et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 2000: 1: 81-88.
21. Turer AT, Scherer PE. Adiponectin: mechanistic insights and clinical implications. Diabetologia 2012: 55: 2319-2326.
22. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001: 86: 1930-1935.
23. Herder C, Schneitler S, Rathmann W et al. Low-grade inflammation, obesity, and insulin resistance in adolescents. J Clin Endocrinol Metab 2007: 92: 4569-4574.
24. Tabak AG, Brunner EJ, Miller MA et al. Low serum adiponectin predicts 10-year risk of type 2 diabetes and HbA1c independently of obesity, lipids, and inflammation: Whitehall II study. Horm Metab Res 2009: 41: 626-629.
25. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006: 6: 772-783.
26. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009: 302: 179-188.
27. Nayak S, Soon SQ, Kunjal R et al. Relationship between adiponectin, inflammatory markers and obesity in type 2 diabetic and non-diabetic Trinidadians. Arch Physiol Biochem 2009: 115: 28-33.
28. Coimbra S, Brandao PJ, Santos-Silva A, Neuparth MJ. Adiponectin, leptin, and chemerin in elderly patients with type 2 diabetes mellitus: a close linkage with obesity and length of the disease. Biomed Res Int 2014: 2014: 701915.
29. Yatagai T, Nagasaka S, Taniguchi A et al. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 2003: 52: 1274-1278.
30. Duncan BB, Schmidt MI, Pankow JS et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 2004: 53: 2473-2478.
31. West NA, Hamman RF, Mayer-Davis EJ et al. Cardiovascular risk factors among youth with and without type 2 diabetes: differences and possible mechanisms. Diabetes Care 2009: 32: 175-180.
32. Su SC, Pei D, Hsieh CH, Hsiao FC, Wu CZ, Hung YJ. Circulating pro-inflammatory cytokines and adiponectin in young men with type 2 diabetes. Acta Diabetol 2011: 48: 113-119.
33. Nadeau KJ, Zeitler PS, Bauer TA et al. Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. J Clin Endocrinol Metab 2009: 94: 3687-3695.
34. Rempel JD, Packiasamy J, Dean HJ et al. Preliminary analysis of immune activation in early onset type 2 diabetes. Int J Circumpolar Health 2013: 72. doi: 10.3402/ijch.v72i0.21190.
35. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 2000: 23: 381-389.
36. Awa WL, Boehm BO, Rosinger S et al. HLA-typing, clinical, and immunological characterization of youth with type 2 diabetes mellitus phenotype from the German/Austrian DPV database. Pediatr Diabetes 2013: 14: 562-574.
37. Reinehr T, Hinney A, de Sousa G, Austrup F, Hebebrand J, Andler W. Definable somatic disorders in overweight children and adolescents. J Pediatr 2007: 150: 618-622.
38. Cole TJ. The LMS method for constructing normalized growth standards. Eur J Clin Nutr 1990: 44: 45-60.
39. Kromeyer-Hauschild K, Wabitsch M, Geller F et al. Percentiles of body mass index in children and adolescents evaluated from different regional German studies. Monatsschr Kinderheilkd 2001: 149: 807-818.
40. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000: 320: 1240-1243.
41. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004: 114 (2 Suppl. 4th Report): 555-576.
42. Berglund ED, Vianna CR, Donato J Jr et al. Direct leptin action on POMC neurons regulates glucose homeostasis and hepatic insulin sensitivity in mice. J Clin Invest 2012: 122: 1000-1009.
43. Cummings BP, Bettaieb A, Graham JL et al. Subcutaneous administration of leptin normalizes fasting plasma glucose in obese type 2 diabetic UCD-T2DM rats. Proc Natl Acad Sci USA 2011: 108: 14670-14675.
44. Moon HS, Matarese G, Brennan AM et al. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance. Diabetes 2011: 60: 1647-1656.
45. Mittendorfer B, Horowitz JF, DePaoli AM, McCamish MA, Patterson BW, Klein S. Recombinant human leptin treatment does not improve insulin action in obese subjects with type 2 diabetes. Diabetes 2011: 60: 1474-1477.
46. Yaghootkar H, Lamina C, Scott RA et al. Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 2013: 62: 3589-3598.
47. Miazgowski T, Dziwura-Ogonowska J, Safranow K, Iskierska K, Widecka K. Changes in adiponectin level and fat distribution in patients with type 2 diabetes. Eur J Clin Invest 2014: 44: 192-199.
48. Neuparth MJ, Proenca JB, Santos-Silva A, Coimbra S. Adipokines, oxidized low-density lipoprotein, and C-reactive protein levels in lean, overweight, and obese Portuguese patients with type 2 diabetes. ISRN Obes 2013: 2013: 142097.
49. Maahs DM, Hamman RF, D'Agostino R Jr et al. The association between adiponectin/leptin ratio and diabetes type: the SEARCH for Diabetes in Youth Study. J Pediatr 2009: 155: 133-135.
50. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006: 116: 1784-1792.
51. Costacou T, Zgibor JC, Evans RW et al. The prospective association between adiponectin and coronary artery disease among individuals with type 1 diabetes. The Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2005: 48: 41-48.
52. Saito T, Murata M, Otani T, Tamemoto H, Kawakami M, Ishikawa SE. Association of subcutaneous and visceral fat mass with serum concentrations of adipokines in subjects with type 2 diabetes mellitus. Endocr J 2012: 59: 39-45.